Cancers: DMMR/MSI metastatic colorectal cancer (MCRC) treatment failed after the treatment
Mistration repair genetic defect/microbriet unstable instability (DMMR/MSI) metastatic colorectal cancer (MCRC) uses traditional therapy (CT, chemotherapy combined or non -combined targeted therapy) The effect is not clear.
<!–
->
Therefore, foreign researchers have carried out relevant research to evaluate the effect of using CT treatment after the failure of DMMR/MSI metastatic colorectal cancer (MCRC) treatment. Related results were published in Cancers magazine.
A total of 31 patients with DMMR/MSI MCRC were included from June 2015 to January 2020. When the ICI treatment starts treatment, the median age is 56 years old, and 58%of patients ECOG 0 -1. Most patients (84%) have two or more metastasis parts. The most common are lymph nodes (77%), peritoneum (65%), and liver (52%). 26%of patients have mutations in RAS or BRAF V600E, and 1 of patients with RAS and Braf V600E mutations at the same time. Overall, 39%and 29%of patients were diagnosed with Linqi syndrome and originated.
Before ICI treatment, 48%of patients received two or more chemotherapy programs targeted therapy, and 100%, 94%, and 68%were exposed to fluoropicidine, Osarbin, and Ilidekang. The median PFS of the last chemotherapy of ICI was 3.7 months (95%CI [2.66-8.36]), and DCR and ORR were 52%and 16%, respectively.
In ICI treatment, 71%of patients (anti-PD-1, N = 15, anti-PDL-1, n = 7) were treated with anti-PD (L) -1 single drugs, and 9 patients were treated with combined treatment. The median time for ICI treatment is 5.6 months (95%CI [3.5-10.9]), DCR is 65%, and ORR is 16%.
After ICI was treated, the main chemotherapy scheme was Folfox (29%), Folfiri (29%), or sosomin (16%). The monoclonal antibody scheme was 39%and 19%, respectively.
After the progress of the ICI progress, the median follow -up time was 23.8 months, and the DCR was 45%, of which 4 were PR and 10 cases of SD. Mid -position PFS and OS are 2.9 months (95% CI [2.07–6.39]) and 7.4 months (95% CI [4.49–12.2]).
Prognostic factors found that only ECOG ≧ 2 is related to the poor PFS (HR = 2.22, 95%CI 1.03, 4.77, P = 0.045), but it is not significant to OS.
In summary, studies have shown that previous ICI treatment does not enhance the efficacy of subsequent traditional treatment, but the sample volume is limited, and further verification is required for follow -up.
Primitive source:
BUI, Q.L.; MAS, L.; Hollebecque, A.; Tougeron, D.; de La Fouchaardière, C.; Pudlarz, T.; ALouani, E.; Gumbaud, R.; TAIEB, J.; André, T. T. T. T. T. T. T. T. T. T. T. T. T. T. T. T. T. T. T. T. T. T. T. T. T. T. T. T. T. T. T. T. T. T. T. T. T. T. T. t. t. t. t. t. t?; André, t. t. t. t. t. t. t. t. t. ; ET Al. Treatments after Immune Checkpoint inhibitors in Patients with DMMR/MSI Metastatic CORORECTAL CANCER.
